(5-氨基吡啶-3-基)硼酸盐酸盐, 98%

(5-Aminopyridin-3-yl)boronic acid hydrochloride

(5-氯-2,4-二氟苯基)硼酸, 98%

(5-Chloro-2,4-difluorophenyl)boronic acid

(5-溴吡啶-3-基)(苯基)甲酮, ≥98%

(5-Bromopyridin-3-yl)(phenyl)methanone

(6-溴吡啶-2-基)乙酸乙酯, ≥98%

Ethyl 2-(6-bromopyridin-2-yl)acetate

(6-甲基-1H-苯并[d]咪唑-2-基)甲醇, ≥98%

(6-Methyl-1H-benzo[d]imidazol-2-yl)methanol

(6-甲氧基吡啶-3-基)甲胺二盐酸盐, ≥98%

(6-Methoxypyridin-3-yl)methanamine dihydrochloride

(6bR,10aS)-3-甲基-2,3,6b,7,10,10a-六氢-1H-吡啶并[3',4'：4,5]吡咯并[1,2,3-de]喹喔啉-8(9H)-羧酸叔丁酯, 98%

(6bR,10aS)-Ethyl 3-methyl-2,3,6b,7,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline-8(9H)-carboxylate

(7-((((9H-芴-9-基)甲氧基)羰基)氨基)-2-氧代-2H-色烯-4-基)乙酸, ≥98%

2-(7-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2-oxo-2H-chromen-4-yl)acetic acid

(9H-芴-9-基)甲基3-羟基吖丁啶-1-羧酸酯, 98%

(9H-Fluoren-9-yl)methyl 3-hydroxyazetidine-1-carboxylate

(alphaR)-alpha-[[[2-(4-硝基苯基)乙基]氨基]甲基]苯甲醇, 99%

(R)-2-((4-Nitrophenethyl)amino)-1-phenylethanol

(alphaS)-alpha-氨基-N-[(1R)-1-[(3aS,4S,6S,7aR)-六氢-3a,5,5-三甲基-4,6-甲桥-1,3,2-苯并二氧硼烷-2-基]-3-甲基丁基]苯丙酰胺盐酸盐, 98%

Bortezomib intermediates II

(E)-2-((二甲基氨基)亚甲基)-3-氧代丁酸甲酯, 98%

(E)-Methyl 2-((dimethylamino)methylene)-3-oxobutanoate

(E)-2-[2-(6-氯嘧啶-4-基氧)苯基]-3-甲氧基丙烯酸甲酯, 98%

(E)-Methyl 2-(2-((6-chloropyrimidin-4-yl)oxy)phenyl)-3-methoxyacrylate

(5-溴苯并[d][1,3]-二氧杂环戊烯-4-基)氨基甲酸叔丁酯, ≥98%

tert-Butyl (5-bromobenzo[d][1,3]dioxol-4-yl)carbamate

(5-苯基吡啶-3-基)甲醇, ≥98%

(5-Phenylpyridin-3-yl)methanol

(6-氯吡啶-2-基)甲胺二盐酸盐, ≥98%

(6-Chloropyridin-2-yl)methanamine dihydrochloride

(6-氯咪唑并[1,2-b]哒嗪-3-基)(苯基)甲酮, 98%

(6-Chloroimidazo[1,2-b]pyridazin-3-yl)(phenyl)methanone

(R)-(1,4-二恶烷-2-基)甲醇, 98%

(R)-(1,4-Dioxan-2-yl)methanol

(R)-(2-氧代吡咯烷-3-基)氨基甲酸叔丁酯, ≥98%

(R)-tert-Butyl (2-oxopyrrolidin-3-yl)carbamate

(R)-(2-羟基-2-苯乙基)(4-硝基苯乙基)氨基甲酸叔丁酯, ≥98%

(R)-tert-Butyl (2-hydroxy-2-phenylethyl)(4-nitrophenethyl)carbamate